Beskrivning
| Land | Norge |
|---|---|
| Lista | OAX Equities |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
2022-02-03 18:19:02
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED
STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE
PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE
DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.
PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS STOCK EXCHANGE
Reference is made to the stock exchange announcement published by Observe
Medical ASA (the "Company") on 14 January 2022, regarding a proposed fully
underwritten rights issue (the "Rights Issue"), which is subject to the approval
by the extraordinary general meeting of the Company to be held at 10:00 (CET) on
4 February 2022.
The Company's board of directors has today, on 3 February 2022, based on a
recommendation from Carnegie AS and DNB Markets, a part of DNB Bank ASA (acting
as "Managers" in the Rights Issue), determined the following proposed (i)
subscription price, (ii) number of new shares and (iii) share capital increase
pertaining to the Rights Issue:
· The subscription price is proposed to be NOK 7.0 per new share offered in
the Rights Issue (the "Offer Shares"), representing a discount of 30% to the
theoretical ex rights price (TERP) of the Company's shares based on the volume
-weighted average price (VWAP) of the Company's shares on Euronext Expand in the
three days' period from 1 February 2022 to and including 3 February 2022, of NOK
13.939